Blair Brengle
Family Medicine · Indianapolis, INNPI 1023014420
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (50.4%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Eli Lilly accounts for 67.0% of it on its own, with 24 other manufacturers making up the rest. Reporting peaked in 2023 at $8,469 and has fallen 70.0% since, to $2,540 in 2025. Among family medicine clinicians in IN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 313 payments — averaging $54.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly$11K
- Novo Nordisk$1K
- AbbVie$1K
- Lilly USA, LLC$855
- Novartis$409
- Bayer$252
- plus $1K from 19 others
Across 763 payments — averaging $15,992 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$9.7M
- Sanofi Pasteur Inc.$2.4M
- Novartis$29K
- Novo Nordisk AS$29K
- Sanofi$17K
- Cue Health Inc.$10K
- plus $4K from 1 others
What the payments were for
- Consulting fees$8,60050%
- Travel & lodging$2,04712%
- Food & beverage$6,29737%
- Education$1301%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eli Lilly | 36 | $11,434 |
| Novo Nordisk | 71 | $1,471 |
| AbbVie(2 entities) | 52 | $1,211 |
| Lilly USA, LLC | 43 | $855 |
| Novartis | 23 | $409 |
| Bayer | 12 | $252 |
| Harmony Biosciences LLC | 5 | $161 |
| Pfizer | 9 | $159 |
| Astellas Pharma US Inc | 7 | $133 |
| Currax Pharmaceuticals LLC | 9 | $121 |
| Amgen | 6 | $115 |
| Biohaven Pharmaceutical Holding Company Ltd. | 5 | $91 |
| AstraZeneca | 5 | $84 |
| Otsuka America Pharmaceutical, Inc. | 3 | $77 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $75 |
| GSK | 3 | $74 |
| Idorsia Pharmaceuticals US Inc | 4 | $70 |
| Abbott | 3 | $59 |
| Sanofi-aventis U.S. LLC | 3 | $53 |
| Avadel CNS Pharmaceuticals, LLC | 2 | $40 |
| Endo Pharmaceuticals Inc. | 2 | $37 |
| Ironshore Pharmaceuticals Inc. | 2 | $33 |
| Merz North America, Inc. | 1 | $32 |
| Johnson & Johnson | 1 | $14 |
| Boehringer Ingelheim | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$17,074 in reported general payments places this provider in the 95th percentile of 2,709 family medicine providers in Indiana.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 36 | $43,187 |
| OzempicSemaglutide | 38 | $40,074 |
| EntrestoSacubitril/Valsartan | 24 | $32,834 |
| EliquisApixaban | 29 | $18,592 |
| RybelsusSemaglutide | 19 | $17,857 |
| FarxigaDapagliflozin Propanediol | 11 | $16,438 |
| Xigduo XrDapaglifloz Propaned/Metformin | 11 | $5,440 |
| Nebivolol Hcl | 17 | $1,688 |
| Pregabalin | 13 | $882 |
| Codeine Sulfate | 13 | $882 |
| Tramadol Hcl | 21 | $814 |
| Insulin Degludec Pen (U-200)Insulin Degludec | 11 | $769 |
| Metoprolol Succinate | 29 | $657 |
| Atorvastatin Calcium | 84 | $653 |
| Mirtazapine | 17 | $648 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $1,471 | $57,93157 claims |
| Lilly USA, LLCMounjaro, Olanzapine | $855 | $43,73148 claims |
| NovartisEntresto | $409 | $32,83424 claims |
| PfizerEliquis | $159 | $18,59229 claims |
| AstraZenecaFarxiga | $84 | $16,43811 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,709 family medicine providers in Indiana.
Other family medicine in Indianapolis
- Richard TannerIndianapolis$1.6M
- Richard FeldmanIndianapolis$476K
- Joe BanksIndianapolis$294K
- Jakoda SniderIndianapolis$107K
- Robert ClutterIndianapolis$77K
- James AndryBloomington$715K
- Anthony InzerelloEvansville$308K
- Steven GatewoodElwood$281K
- Shekar PushpalaCarmel$239K
- Victoria MoyerKokomo$188K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.